Amarin Corporation plc (AMRN) is a Healthcare stock trading at $13.84 (as of 2026-09-01). Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing cardiovascular therapeutics, with operations in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its prescription-only product VASCEPA is indicated as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia, and it is sold primarily through wholesalers and specialty pharmacy providers.
Valuation — source: SEC EDGAR (first-party)
Price
$13.84
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)
$213.65M
Net Margin
-18.2%
Return on Equity
-6.1%
Current Ratio
3.67
Revenue Growth (YoY)
-42.0%
EPS Growth (YoY)
-33.3%
Financial Health — source: SEC EDGAR
Altman Z-Score
13.66 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)
21.6
Industry P/E (Pharmaceutical Products)
17.2
Company
Sector
Healthcare
Industry
Pharmaceutical Products
CEO
Aaron D. Berg
Employees
275
Country
IE
IPO Date
1993-04-01
Related Companies (Pharmaceutical Products; 8 comparable drugmakers)